Meeting
2021 Gastrointestinal Cancers Symposium
Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).
Authors
Hiromichi Shirasu
Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan
Hiromichi Shirasu , Takeshi Kawakami , Satoshi Hamauchi , Takahiro Tsushima , Akiko Todaka , Tomoya Yokota , Kentaro Yamazaki , Akira Fukutomi , Yusuke Onozawa , Hirofumi Yasui
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Pancreatic Cancer
Track
Pancreatic Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 407)
DOI
10.1200/JCO.2021.39.3_suppl.407
Abstract #
407
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2020 ASCO Virtual Scientific Program
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study.
First Author: Hortense Chevalier
Poster
2020 Gastrointestinal Cancers Symposium
Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study.
First Author: Laura Gutiérrez Sainz